Parabilis Medicines, Inc. (PBLS) stock
PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$28.25−0.20 (-0.70%)
Close on Nov 17, 2026Market cap $3.49BP/E –Yield –
Parabilis Medicines ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$50.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$36.32M | – |
See a number that looks wrong?